SCHEMBL7215817

SCHEMBL7215817

CCCOCCOc1ccc(COc2ccc3c(c2)C=C(C(=O)OC)CCS3(=O)=O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.38
RAB9A P51151 6/20 0.38
MAPT P10636 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
APP P05067 2/20 0.36
HRH3 Q9Y5N1 1/20 0.36
KDM4E B2RXH2 2/20 0.34
LMNA P02545 2/20 0.34
PPARG P37231 1/20 0.34
PPARD Q03181 1/20 0.34
PPARA Q07869 1/20 0.34
ALDH1A1 P00352 3/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HPGD P15428 1/20 0.33
USP2 O75604 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7222803 0.94 NPC1 (0.38) NPC1RAB9AMAPTSMN1; SMN2MEN1
SCHEMBL7218242 0.94 NPC1 (0.37) NPC1RAB9AMAPTSMN1; SMN2MEN1
SCHEMBL7215961 0.91 HRH3 (0.39) NPC1RAB9ASMN1; SMN2KMT2AAPP
SCHEMBL7216131 0.90 MAPT (0.36) RAB9AMAPTSMN1; SMN2KDM4ELMNA
SCHEMBL7218076 0.89 S1PR1 (0.36) MAPTSMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL7218066 0.89 NPC1 (0.41) NPC1RAB9AMAPTSMN1; SMN2MEN1
SCHEMBL7975157 0.88 RARB (0.40) RAB9AMAPTKDM4ELMNA
SCHEMBL7218022 0.87 ACACB (0.38) RAB9AMAPTKMT2AHRH3KDM4E
SCHEMBL7218151 0.86 PPARD (0.34) MAPTSMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL7221547 0.86 LMNA (0.40) NPC1RAB9AMAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed